Atom | Elucidating Immunometabolic Responses to HIV Infection that Increase TB or HBV Risk (R21 Clinical Trial Not Allowed)

Funder: National Institutes of Health

Due Dates: May 7, 2025 (AIDS) | Sep 7, 2025 | Jan 7, 2026 | May 7, 2026 | Sep 7, 2026 | Jan 7, 2027 | May 7, 2027 | Sep 7, 2027 | Jan 7, 2028

Funding Amounts: Up to $275,000 direct costs over 2 years; no more than $200,000 in any single year; project period max 2 years.

Summary: Supports exploratory research on how HIV-induced immunometabolic changes in cART-suppressed individuals increase risk and worsen outcomes for TB or HBV co-infection.

Key Information: Clinical trials are not allowed; foreign and domestic applicants eligible; updated March 2025—review full NOFO for changes.

Elucidating Immunometabolic Responses to HIV Infection that Increase TB or HBV Risk (R21 Clinical Trial Not Allowed)

Sign in to see full grant listing